A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest-Reference-Cited by-同舟云学术

A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest

Published:2021 Issue:1 Volume:49 Page:39-49
ISSN:1073-1105
Container-title:Journal of Law, Medicine & Ethics
language:en
Short-container-title:J. Law. Med. Ethics

Author:

Mazzucato Mariana,Li Henry Lishi

Abstract

AbstractEnhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.

Publisher

Cambridge University Press (CUP)

Subject

Health Policy,General Medicine,Issues, ethics and legal aspects

Reference85 articles.

1. 75. Lazonick, W. , “Profits Without Prosperity: How Stock Buy-backs Manipulate the Market and Leave Most Americans Worse Off,” Institute for New Economic Thinking Conference Paper (2014), available at (last visited February 22, 2021).

2. 80. Whitfill, supra note 25.

3. Economic Theories about the Benefits and Costs of Patents

4. 78. Office of U.S. Senator Elizabeth Warren of Massachusetts, COVID-19 Emergency Manufacturing Act of 2020, introduced by Senator Elizabeth Warren (D-MA) and Representative Jan Schakowsky (D-IL) (2020).

5. Global Drug Shortages Due to COVID-19: Impact on Patient Care and Mitigation Strategies,;Badreldin;Research in Social and Administrative Pharmacy,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models;Globalization and Health;2024-03-26

2. COVID and structural cartelisation: market-state-society ties and the political economy of Pharma;New Political Economy;2024-01-19

3. “A Most Equitable Drug”: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development;Journal of Law, Medicine & Ethics;2024

4. Shared health governance, mutual collective accountability, and transparency in COVAX: A qualitative study triangulating data from document sampling and key informant interviews;Journal of Global Health;2023-12-08

5. Which roads lead to access? A global landscape of six COVID-19 vaccine business models.;2023-12-05